Regina Cseuz

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 359 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +14

Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)

Arthur Kavanaugh, Joel M. Kremer, L Ponce et al. · Annals of the Rheumatic Diseases · 2016 · 230 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Changes of Adrenergic Reaction Pattern in Experimental Diabetes Mellitus

Regina Cseuz, Thomas L. Wenger, George Kunos et al. · Endocrinology · 1973 · 36 citations

Medicine, Endocrinology, Physiology +9

THE INHIBITION OF NK CELL FUNCTION BY AZATHIOPRINE DURING THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

Regina Cseuz, G. S. Panayi · Lara D. Veeken · 1990 · 16 citations

Medicine, Immunology, Pharmacology +14

THU0173 Filgotinib (GLPG0634), An Oral Jak1 Selective Inhibitor Is Effective as Monotherapy in Patients with Active Rheumatoid Arthritis: Results from A 24-Week Phase 2B Dose Ranging Study

Arthur Kavanaugh, L Ponce, Regina Cseuz et al. · Annals of the Rheumatic Diseases · 2016 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +14